At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,513 enrolled
Drug / intervention
MK0954, losartan / Duration of Treatment: mean 3.4 years +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Renal Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes Mellitus and Nephropathy
In Brief
A Phase 3 clinical trial evaluating MK0954, losartan / Duration of Treatment: mean 3.4 years and Placebo / Duration of Treatment: mean 3.4 years for Type 2 Diabetes and Nephropathy. Completed, enrolled 1,513 participants.
Detailed Summary
Evaluate the effect of Losartan in reducing kidney disease in patients with Non-insulin Dependent Diabetes and Nephropathy (kidney damage that usually accompanies late stage Diabetes Mellitus).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes, Nephropathy
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
19961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 1996
Primary CompletionFeb 2001
Study CompletionApr 2001
First PostedMar 2006
TodayJul 2026
First PostedMar 29, 2006
Enrollment StartMay 1, 1996
Primary CompletionFeb 1, 2001
Study CompletionApr 1, 2001
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 20.3 years ago
Interventions
MK0954, losartan / Duration of Treatment: mean 3.4 yearsdrug
Placebo / Duration of Treatment: mean 3.4 yearsdrug